It is well documented that one of the key targets of metformin is adenosine monophosphate-activated protein kinase (AMPK), which inhibits the mammalian target of rapamycin (mTOR) and therefore suppresses cell proliferation, induces apoptosis and upregulates tumour suppressor genes and proteins [34]. This evidence concerns the gene MTOR and neoplasm.